Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling

[1]  J. Abramowitz,et al.  Obsessive-compulsive disorder , 2006, The Lancet.

[2]  J. Borrell.  NEUROBEHAVIORAL AND IMMUNOLOGICAL CONSEQUENCES OF PRENATAL IMMUNE ACTIVATION IN RATS , 2008, Schizophrenia Research.

[3]  B. Castellano,et al.  Neurobehavioral and Immunological Consequences of Prenatal Immune Activation in Rats. Influence of Antipsychotics , 2007, Neuropsychopharmacology.

[4]  A. Minassian,et al.  Sensorimotor Gating Deficits in Adults with Autism , 2007, Biological Psychiatry.

[5]  H. Nawa,et al.  Recent progress in animal modeling of immune inflammatory processes in schizophrenia: Implication of specific cytokines , 2006, Neuroscience Research.

[6]  P. Murray.  Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. , 2006, Current opinion in pharmacology.

[7]  Christoph Schmitz,et al.  The Developmental Neurobiology of Autism Spectrum Disorder , 2006, The Journal of Neuroscience.

[8]  Urs Meyer,et al.  The Time of Prenatal Immune Challenge Determines the Specificity of Inflammation-Mediated Brain and Behavioral Pathology , 2006, The Journal of Neuroscience.

[9]  J. Feldon,et al.  Prenatal and postnatal maternal contributions in the infection model of schizophrenia , 2006, Experimental Brain Research.

[10]  K. Hashimoto,et al.  Immune Activation During Pregnancy in Mice Leads to Dopaminergic Hyperfunction and Cognitive Impairment in the Offspring: A Neurodevelopmental Animal Model of Schizophrenia , 2006, Biological Psychiatry.

[11]  S. Poole,et al.  The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia , 2006, Molecular Psychiatry.

[12]  Urs Meyer,et al.  Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia , 2005, Neuroscience & Biobehavioral Reviews.

[13]  J. Feldon,et al.  The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice , 2005, Behavioural Brain Research.

[14]  A. Addington,et al.  The neurodevelopmental model of schizophrenia: update 2005 , 2005, Molecular Psychiatry.

[15]  J L Rapoport,et al.  The neurodevelopmental model of schizophrenia: update 2005 , 2005, Molecular Psychiatry.

[16]  S. Fatemi.  Neuropsychiatric Disorders and Infection , 2005 .

[17]  P. Patterson,et al.  Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus , 2005, International Journal of Developmental Neuroscience.

[18]  P. Rodier,et al.  The teratology of autism , 2005, International Journal of Developmental Neuroscience.

[19]  Lin He,et al.  An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population , 2004, Schizophrenia Research.

[20]  Stephen Kent,et al.  The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[21]  John H Gilmore,et al.  Prenatal Infection and Risk for Schizophrenia: IL-1β, IL-6, and TNFα Inhibit Cortical Neuron Dendrite Development , 2004, Neuropsychopharmacology.

[22]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[23]  John H Gilmore,et al.  Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. , 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[24]  B. Brandner,et al.  Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers , 2004, Neuropsychopharmacology.

[25]  J. Lieberman,et al.  Provocative tests with psychostimulant drugs in schizophrenia , 2004, Psychopharmacology.

[26]  I. Weiner,et al.  Immune Activation During Pregnancy in Rats Leads to a PostPubertal Emergence of Disrupted Latent Inhibition, Dopaminergic Hyperfunction, and Altered Limbic Morphology in the Offspring: A Novel Neurodevelopmental Model of Schizophrenia , 2003, Neuropsychopharmacology.

[27]  W. Pan,et al.  Interleukin-10 as a CNS therapeutic: the obstacle of the blood-brain/blood-spinal cord barrier. , 2003, Brain research. Molecular brain research.

[28]  I. Weiner.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment , 2003, Psychopharmacology.

[29]  Limin Shi,et al.  Maternal Influenza Infection Causes Marked Behavioral and Pharmacological Changes in the Offspring , 2003, The Journal of Neuroscience.

[30]  Peter J. Murray,et al.  Shaping Gene Expression in Activated and Resting Primary Macrophages by IL-101 , 2002, The Journal of Immunology.

[31]  D. Greaves,et al.  Autocrine Deactivation of Macrophages in Transgenic Mice Constitutively Overexpressing IL-10 Under Control of the Human CD68 Promoter1 , 2002, The Journal of Immunology.

[32]  J. Borrell,et al.  Prenatal Immune Challenge Disrupts Sensorimotor Gating in Adult Rats: Implications for the Etiopathogenesis of Schizophrenia , 2002, Neuropsychopharmacology.

[33]  E. Susser,et al.  In utero infection and adult schizophrenia. , 2002, Mental retardation and developmental disabilities research reviews.

[34]  M. Popoli,et al.  Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia , 2001, European Neuropsychopharmacology.

[35]  R. Yolken,et al.  Maternal Cytokine Levels during Pregnancy and Adult Psychosis , 2001, Brain, Behavior, and Immunity.

[36]  G. Griebel,et al.  Measuring normal and pathological anxiety-like behaviour in mice: a review , 2001, Behavioural Brain Research.

[37]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[38]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[39]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[40]  Daniel R Weinberger,et al.  To Model a Psychiatric Disorder in Animals: Schizophrenia As a Reality Test , 2000, Neuropsychopharmacology.

[41]  N. Swerdlow,et al.  Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. , 2000, Behavioural pharmacology.

[42]  M. Laruelle,et al.  Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.

[43]  M. Bakhiet,et al.  Human first trimester forebrain cells express genes for inflammatory and anti-inflammatory cytokines. , 1999, Cytokine.

[44]  Jau-Shyong Hong,et al.  Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures , 1998, Journal of Neuroimmunology.

[45]  P. Carvey,et al.  Differentiation of Mesencephalic Progenitor Cells into Dopaminergic Neurons by Cytokines , 1998, Experimental Neurology.

[46]  J. Gilmore,et al.  Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro , 1997, International Journal of Developmental Neuroscience.

[47]  J. Meis,et al.  A primer on cytokines: sources, receptors, effects, and inducers , 1997, Clinical microbiology reviews.

[48]  J. Gilmore,et al.  Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia , 1997, Schizophrenia Research.

[49]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[51]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[52]  M. Geyer,et al.  Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. , 1993, The American journal of psychiatry.

[53]  N. Swerdlow,et al.  A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder , 1993, Biological Psychiatry.

[54]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[55]  T. Mosmann,et al.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.

[56]  J. Gray,et al.  Differential Performance of Acute and Chronic Schizophrenics in a Latent Inhibition Task , 1988, The Journal of nervous and mental disease.

[57]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.